Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | HINT1 | P49773 | 9/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476426 | 0.89 | TAAR1 (0.44) | TAAR1GSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL2215956 | 0.85 | TAAR1 (0.42) | TAAR1GSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL2401085 | 0.85 | STING1 (0.51) | TAAR1GSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL2107377 | 0.85 | TAAR1 (0.41) | TAAR1GSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL15841326 | 0.84 | TAAR1 (0.40) | TAAR1GSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL9964274 | 0.76 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL22983981 | 0.76 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL20149810 | 0.76 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL14946363 | 0.76 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL25504648 | 0.76 | STING1 (0.60) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3098230-B1 | THIOETHER COMPOUND FOR THE PROTECTION OF THE 2'-HYDROXY GROUP IN NUCLEOSIDES TO BE USED IN OLIGONUCLEOTIDE SYNTHESIS. | BONAC CORP (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-9988415-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2018-06-05 | — | — | US | disclosed |
| EP-2749565-B1 | NUCLEOSIDE PHOSPHORAMIDATES FOR PRODUCING NUCLEIC ACIDS | BONAC CORP (JP) | 2017-05-31 | — | — | EP | disclosed |
| EP-3098230-A1 | THIOETHER COMPOUND FOR THE PROTECTION OF THE 2'-HYDROXY GROUP IN NUCLEOSIDES TO BE USED IN OLIGONUCLEOTIDE SYNTHESIS. | Bonac Corporation (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9481702-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2016-11-01 | — | — | US | disclosed |
| US-20160176810-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | BONAC CORPORATION (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | BONAC CORPORATION (JP) | 2014-07-24 | — | — | US | disclosed |
| EP-2749565-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | Bonac Corporation (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-8158774-B2 | Method for introducing a nucleic-acid protecting group | NIPPON SHINYAKU CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176810-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | DDOST, TENT4A, TRDMT1 | TAAR1 2080/4885GSK3A 3476/4885RPS6KA3 2455/4885 |
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | DDOST, TENT4A, TRDMT1 | TAAR1 2080/4885GSK3A 3476/4885RPS6KA3 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.